MCID: ACT042
MIFTS: 44

Acute Pyelonephritis

Categories: Nephrological diseases

Aliases & Classifications for Acute Pyelonephritis

MalaCards integrated aliases for Acute Pyelonephritis:

Name: Acute Pyelonephritis 12 54 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:559
ICD9CM 34 590.1
NCIt 49 C123215
SNOMED-CT 67 22352007 36689008
ICD10 32 N10
UMLS 71 C0520575

Summaries for Acute Pyelonephritis

MalaCards based summary : Acute Pyelonephritis is related to cystitis and toxic shock syndrome. An important gene associated with Acute Pyelonephritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Akt Signaling and PAK Pathway. The drugs leucovorin and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Acute Pyelonephritis

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Acute Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 620)
# Related Disease Score Top Affiliating Genes
1 cystitis 31.2 IL6 CXCL8 CXCL10 CRP
2 toxic shock syndrome 31.0 IL6 IL10 CXCL8 CRP
3 bacteriuria 31.0 IL6 CXCR2 CXCR1 CXCL8 CRP
4 acute kidney failure 30.8 LCN2 GPT ALB
5 prostatitis 30.7 IL6 IL10 CXCL8
6 hydronephrosis 30.7 NAGLU IL6 CXCL8 CRP ALB
7 diverticulitis 30.5 IL6 CRP ALB
8 pyuria 30.4 LCN2 IL6 GPT CXCL8 CRP ALB
9 chronic pyelonephritis 30.4 CALCA ALB ACE
10 neutrophil migration 30.4 CXCR2 CXCR1 CXCL8
11 urethritis 30.3 IL6 CXCL8 CRP
12 splenic abscess 30.3 GPT CRP ALB
13 neutrophilia, hereditary 30.3 IL6 CSF3 CRP
14 urinary tract obstruction 30.3 NAGLU LCN2 CRP ALB ACE
15 interstitial nephritis 30.3 CRP ALB ACE
16 septic arthritis 30.2 CXCL8 CRP CALCA
17 vaginitis 30.2 IL6 IL10 CXCL8
18 vesicoureteral reflux 1 30.2 NAGLU LCN2 CXCR1 CXCL8 CRP ALB
19 disseminated intravascular coagulation 30.2 IL6 IL10 GPT CRP
20 bacterial infectious disease 30.2 LCN2 IL6 IL10 CXCL8 CSF3 CRP
21 epidural abscess 30.1 CRP ALB
22 analbuminemia 30.1 GPT CRP ALB
23 end stage renal failure 30.0 IL6 CRP CALCA ALB ACE
24 acute cystitis 30.0 LCN2 IL6 IL10 GPT CXCL8 CRP
25 scrub typhus 30.0 LCN2 IL10 GPT CRP
26 cholelithiasis 30.0 GPT CRP ALB
27 obstructive nephropathy 30.0 LCN2 ALB ACE
28 pyomyositis 30.0 CSF3 CRP
29 brucellosis 30.0 IL6 IL10 CXCL8 CRP
30 aortic aneurysm, familial abdominal, 1 29.9 IL6 CRP ACE
31 posterior urethral valves 29.9 IL6 ACE
32 anuria 29.9 LCN2 CRP ALB ACE
33 melioidosis 29.9 IL6 IL10 CSF3
34 pulmonary embolism 29.9 CRP ALB ACE
35 optic papillitis 29.9 CRP ACE
36 glomerular disease 29.9 ALB ACE
37 sickle cell anemia 29.8 IL6 CSF3 ALB
38 thrombocytosis 29.8 IL6 CSF3 CRP ALB
39 acute kidney tubular necrosis 29.8 NAGLU LCN2 IL6 ALB ACE
40 salmonellosis 29.7 IL6 IL10 GPT ALB
41 nephrolithiasis, calcium oxalate 29.7 NAGLU LCN2 CRP CALCA ALB ACE
42 bacterial meningitis 29.7 IL6 IL10 CXCL8 CRP ALB
43 arthritis 29.7 IL6 IL10 CXCL8 CRP ALB
44 crohn's disease 29.6 IL6 IL10 CXCL8 CRP ALB
45 fatty liver disease 29.6 IL6 GPT CXCL8 CRP ALB
46 acute cholangitis 29.6 IL6 GPT CRP CALCA ALB
47 atrial fibrillation 29.6 IL6 CRP ALB ACE
48 discitis 29.5 CRP CALCA
49 appendicitis 29.5 IL6 IL10 CXCL8 CSF3 CRP ALB
50 pyelitis 29.5 LCN2 IL6 CXCR1 CXCL8 CRP ALB

Graphical network of the top 20 diseases related to Acute Pyelonephritis:



Diseases related to Acute Pyelonephritis

Symptoms & Phenotypes for Acute Pyelonephritis

GenomeRNAi Phenotypes related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.58 NAMPT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.58 NAMPT
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 9.58 NAMPT
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.58 NAMPT
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.58 CRP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.58 ESM1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.58 NAMPT
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.58 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 9.58 NAMPT
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.58 NAMPT
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.58 IL10
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.58 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.58 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.58 CRP ESM1 IL10 NAMPT
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.58 CRP

MGI Mouse Phenotypes related to Acute Pyelonephritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.1 ACE ADM ALB CRP CXCL10 CXCR2
2 hematopoietic system MP:0005397 10 ACE ADM CSF3 CXCL10 CXCR1 CXCR2
3 immune system MP:0005387 10 ACE ADM ALB CRP CSF3 CXCL10
4 liver/biliary system MP:0005370 9.56 ACE ADM ALB CXCR2 IL10 IL6
5 renal/urinary system MP:0005367 9.23 ACE ADM ALB CSF3 CXCR2 IL6

Drugs & Therapeutics for Acute Pyelonephritis

Drugs for Acute Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4 58-05-9 6006 143
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Sulfamethoxazole Approved Phase 4 723-46-6 5329
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
5
Cefixime Approved, Investigational Phase 4 79350-37-1 54362 5362065
6
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
9
Ofloxacin Approved Phase 4 82419-36-1 4583
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Fluoroquinolones Phase 4
12 Folic Acid Antagonists Phase 4
13 Antiparasitic Agents Phase 4
14 Vitamin B Complex Phase 4
15 Antiprotozoal Agents Phase 4
16 Vitamin B9 Phase 4
17 Antimalarials Phase 4
18 Folate Phase 4
19 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
20 Antitubercular Agents Phase 4
21 Lactams Phase 4
22 Antipyretics Phase 4
23 Analgesics, Non-Narcotic Phase 4
24 Analgesics Phase 4
25 Anti-Infective Agents Phase 4
26 Renal Agents Phase 4
27 Cytochrome P-450 Enzyme Inhibitors Phase 4
28 Topoisomerase Inhibitors Phase 4
29 Anti-Infective Agents, Urinary Phase 4
30 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
31 Anti-Bacterial Agents Phase 4
32
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
33
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
34
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
35
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
36 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
37
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
38
Racepinephrine Approved Phase 3 329-65-7 838
39
Ceftazidime Approved Phase 3 72558-82-8, 78439-06-2 5481173
40
Doripenem Approved, Investigational Phase 3 148016-81-3 73303
41
Avibactam Approved Phase 3 1192500-31-4
42
Sulbactam Approved Phase 3 68373-14-8
43
Vaborbactam Approved, Investigational Phase 3 1360457-46-0
44
Tigecycline Approved Phase 3 220620-09-7 5282044
45
Colistin Approved Phase 3 1066-17-7, 1264-72-8 5311054
46
Fosfomycin Approved Phase 2, Phase 3 23155-02-4 446987
47
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
48
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
49
Pentetic acid Approved Phase 3 67-43-6
50
Ertapenem Approved, Investigational Phase 3 153832-46-3 150610

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Unknown status NCT03179384 Phase 4 Ceftriaxone
2 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence. Completed NCT00136656 Phase 4 antibiotic;antibiotics
3 Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population With Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Trial Comparing Short (7 Days) Antibiotic Treatment With Conventional Treatment (14 Days) Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
4 Randomized Controled Multicentric Trial, of Non Inferiority, Comparing Two Durations of Antibiotherapy (5 Days Versus 10 Days) in COMMUNAUTARY Acute Uncomplicated Pyelonephritis. Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
5 Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux. Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
6 A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin Completed NCT02283203 Phase 4 APOTEL max;Placebo
7 TREATMENT OF ACUTE UNCOMPLICATED PYELONEPHRITIS WITH SHORT COURSE LEVOFLOXACIN A Pilot Study Terminated NCT00239161 Phase 4 Levofloxacin
8 The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
9 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
10 To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection Unknown status NCT02331862 Phase 3 Methylprednisolone
11 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
12 A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
13 A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
14 A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
15 Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
16 A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
17 Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
18 A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
19 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
20 A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Recruiting NCT03788967 Phase 3 Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);Ertapenem
21 A Phase 3, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Cefepime-AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis. Recruiting NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
22 A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis Recruiting NCT03840148 Phase 3 Cefepime/VNRX-5133;Meropenem
23 A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome Recruiting NCT03345992 Phase 3 Clarithromycin;Water for injection
24 A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem Followed by Optional Oral Therapy in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
25 Randomised Controlled Trial on Efficacy and Safety of Short Term Versus Long Term Antibiotic Therapy for Pyelonephritis in Childhood. Terminated NCT00724256 Phase 3 ceftibuten;ceftibuten
26 A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli Unknown status NCT02537847 Phase 2 Sitafloxacin;Ertapenem
27 A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults With Acute Pyelonephritis Completed NCT03757234 Phase 2 Omadacycline;Levofloxacin
28 A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis Completed NCT01096849 Phase 2 levofloxacin;plazomicin;placebo
29 Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis. Completed NCT02080182 Phase 2 Acetylcysteine;placebo acetylcysteine
30 A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT03445195 Phase 2 Sulbactam-ETX2514;Placebo;Imipenem-cilastatin
31 Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis Completed NCT03680612 Phase 2 Cefepime 1G - 2G / AAI101 0.5G - 0.75G;cefepime 1 g or cefepime 2 g
32 A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline Fosamil and NXL104 Versus Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infection Completed NCT01281462 Phase 2 Ceftaroline fosamil and NXL104 (q8h);Ceftaroline fosamil and NXL104 (q12h);Doripenem;Placebo
33 A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation. Completed NCT01928433 Phase 2 Finafloxacin 800 mg i.v. once daily;Finafloxacin placebo i.v. once daily;Finafloxacin 800 mg tablets once daily;Finafloxacin placebo tablets once daily;Ciprofloxacin 400 mg i.v. twice daily;Ciprofloxacin placebo i.v. twice daily;Ciprofloxacin 500 mg oral twice daily;Ciprofloxacin placebo oral twice daily
34 A Randomised, Double-blind, Dose-finding, Multicenter Study of the Safety, Tolerability, and Efficacy of GSK2251052 Therapy Compared to Imipenem-cilastatin in the Treatment of Adult Subjects With Febrile Complicated Lower Urinary Tract Infections and Acute Pyelonephritis Terminated NCT01381549 Phase 2 GSK2251052;imipenem-cilastatin
35 New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency Terminated NCT01628900 Phase 2
36 Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study Unknown status NCT00190281
37 Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR Unknown status NCT02034851
38 Urinary Cytokine Levels as a Prognostic Marker for Kidney Scarring After Pyelonephritis Unknown status NCT00868270
39 Quantitating Proteinuria During Acute Pyelonephritis In Pregnancy Unknown status NCT02536638
40 Kinetics of Procalcitonin, C-reactive Protein and Pyuria in Uncomplicated Pyelonephritis in Women: A Pilot Study Completed NCT00805181
41 Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States Completed NCT01641029
42 Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae Completed NCT02420366
43 Effect of Systematic Search and Antimicrobial Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients in the Incidence of Acute Pyelonephritis: a Pragmatic Prospective Randomized Controlled Study. Completed NCT02373085
44 Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population Recruiting NCT03399682
45 Non-invasive Blood Test to Diagnose Acute Rejection After Pancreas and Kidney Transplantation: Pancreas and Renal Rejection Diagnosis Using Circulating Donor-derived Cell-free DNA in Peripheral Blood Recruiting NCT04166149
46 The Validity of the Quick Renal MRI in Pediatric Kidney Disease Recruiting NCT03959163
47 Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli. Terminated NCT01820793 Cefoxitin
48 Bacterial and Host Genetic Risk Factors That Predispose Children to Acute Pyelonephritis and Renal Scarring Withdrawn NCT01137929

Search NIH Clinical Center for Acute Pyelonephritis

Genetic Tests for Acute Pyelonephritis

Anatomical Context for Acute Pyelonephritis

MalaCards organs/tissues related to Acute Pyelonephritis:

40
Kidney, Liver, Heart, Prostate, Neutrophil, Testes, Bone

Publications for Acute Pyelonephritis

Articles related to Acute Pyelonephritis:

(show top 50) (show all 2273)
# Title Authors PMID Year
1
Clinical implication of serum C-reactive protein in patients with uncomplicated acute pyelonephritis as marker of prolonged hospitalization and recurrence. 54 61
18930516 2009
2
Urinary N-acetyl-beta-D-glucosaminidase as a diagnostic marker of acute pyelonephritis in children. 54 61
19367005 2008
3
Urine interleukin-1beta in children with acute pyelonephritis and renal scarring. 54 61
17803473 2007
4
A genetic basis of susceptibility to acute pyelonephritis. 54 61
17786197 2007
5
Serum and urine levels of interleukin-6 and interleukin-8 in children with acute pyelonephritis. 54 61
17374489 2006
6
Expression of interleukin-8 receptors (CXCR1 and CXCR2) in premenopausal women with recurrent urinary tract infections. 54 61
16339057 2005
7
Chemokine response to febrile urinary tract infection. 54 61
15954896 2005
8
[Assessment of fructose-1,6-biphosphatase in urine of children with acute pyelonephritis]. 54 61
15074024 2004
9
Serum amyloid A: a novel serum marker for the detection of systemic inflammatory response in cystitis. 54 61
12913703 2003
10
Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. 54 61
11404374 2001
11
Symptomatic urinary tract infection in women in primary health care. Bacteriological, clinical and diagnostic aspects in relation to host response to infection. 54 61
8792507 1996
12
Functional parameters and 99mtechnetium-dimercaptosuccinic acid scan in acute pyelonephritis. 54 61
7696107 1994
13
Renal scarring after acute pyelonephritis. 54 61
8129430 1994
14
[NAG (N-acetyl-beta-D-glucosaminidase)--a sensitive marker for disorders of kidney function]. 54 61
2316078 1990
15
Acidosis induces antimicrobial peptide expression and resistance to uropathogenic E. coli infection in kidney collecting duct cells via HIF-1α. 61
31841391 2020
16
Long-term Outcome of Renal Transplantation in Patients with Congenital Lower Urinary Tract Malformations: A Multicenter Study. 61
30964838 2020
17
Sarcomatoid chromophobe renal cell carcinoma revealed by acute pyelonephritis in a diabetic patient. 61
31681535 2020
18
Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital. 61
31431290 2020
19
Alpha-hemolysin of uropathogenic Escherichia coli induces GM-CSF-mediated acute kidney injury. 61
31719643 2020
20
Process Development and Synthesis of Process-Related Impurities of an Efficient Scale-Up Preparation of 5,2'-Dibromo-2,4',5'-Trihydroxy Diphenylmethanone as a New Acute Pyelonephritis Candidate Drug. 61
31979084 2020
21
Evaluation of hematogenous spread and ascending infection in the pathogenesis of acute pyelonephritis due to group B streptococcus in mice. 61
31614193 2020
22
Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales. 61
31520270 2020
23
Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. 61
31970713 2020
24
An update on renal scarring after urinary tract infection in children: what are the risk factors? 61
31591046 2019
25
Association of serum vitamin D levels and urinary tract infection in pregnant women: A case control study. 61
31671292 2019
26
[Immune disturbances in acute pyelonephritis. Part I]. 61
31808651 2019
27
[Bilateral acute purulent destructive pyelonephritis after retrograde ureteroscopy and lithotripsy]. 61
31808644 2019
28
Current Status of Radionuclide Renal Cortical Imaging in Pyelonephritis. 61
31182659 2019
29
Reconsideration of urine culture for the diagnosis of acute pyelonephritis in children: a new challenging method for diagnosing acute pyelonephritis. 61
31870084 2019
30
Is there a simple and less invasive way to accurately diagnose acute pyelonephritis? 61
31870085 2019
31
Perinephric Fat Stranding on Postmortem Computed Tomography Scan in Acute Pyelonephritis: A Case Report. 61
31094715 2019
32
Clinical Predictors Implicated in the Incidence of Acute Pyelonephritis during the Antepartum Period: A Population-Based Cohort Study. 61
31865329 2019
33
Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam With Imipenem/Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis. 61
31843995 2019
34
A rare presentation of an ectopic kidney with pyelonephritis mimicking appendicitis. 61
31768250 2019
35
Urinary tract infection in pediatrics: an overview. 61
31783012 2019
36
Effects on renal outcome of concomitant acute pyelonephritis, acute kidney injury and obstruction duration in obstructive uropathy by urolithiasis: a retrospective cohort study. 61
31685503 2019
37
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. 61
30861061 2019
38
Incidence, risk factors, and clinical outcomes of acute kidney injury associated with acute pyelonephritis in patients attending a tertiary care referral center. 61
30942133 2019
39
Clinical impact of perinephric fat stranding detected on computed tomography in patients with acute pyelonephritis: a retrospective observational study. 61
31372906 2019
40
Antibiotics for asymptomatic bacteriuria in pregnancy. 61
31765489 2019
41
Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections. 61
31614430 2019
42
Resistance to antibacterial therapy in pediatric febrile urinary tract infections-a single-center analysis. 61
31740148 2019
43
Urine Cultures in Acute Pyelonephritis: Knowing What You Are Up Against. 61
31543125 2019
44
Patient-Friendly Summary of the ACR Appropriateness Criteria: Acute Pyelonephritis. 61
31295434 2019
45
Updates on urinary tract infections in kidney transplantation. 61
30689126 2019
46
[Evaluation of susceptibility of multidrug-resistant Pseudomonas aeruginosa strains against ceftolozane/tazobactam]. 61
31859795 2019
47
Ureteral endometriosis in patients with deep infiltrating endometriosis: characteristics and management from a single-center retrospective study. 61
31494695 2019
48
Prolonged fever is not a reason to change antibiotics among patients with uncomplicated community-acquired acute pyelonephritis. 61
31651906 2019
49
CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial. 61
31433059 2019
50
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. 61
31648032 2019

Variations for Acute Pyelonephritis

Expression for Acute Pyelonephritis

Search GEO for disease gene expression data for Acute Pyelonephritis.

Pathways for Acute Pyelonephritis

Pathways related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 PGF IL6 IL10 CXCR2 CXCR1 CXCL8
2
Show member pathways
13.07 PGF IL6 IL10 CXCR2 CXCR1 CXCL8
3
Show member pathways
12.31 LCN2 CXCR2 CXCR1 CXCL8
4
Show member pathways
12.1 LCN2 IL6 CXCL8 CXCL10 CSF3
5 11.79 LCN2 IL6 IL10 CXCL8
6
Show member pathways
11.77 IL6 IL10 CXCR2 CXCR1 CXCL8 CXCL10
7
Show member pathways
11.69 IL6 CXCL8 CSF3
8 11.59 IL6 IL10 CXCL8
9 11.55 IL6 IL10 CXCL10
10 11.39 IL6 CXCR1 CXCL8
11 11.36 IL6 CXCL8 CSF3 CALCA
12 11.16 IL6 IL10 CXCL8 CSF3
13 11.1 IL6 IL10 CSF3
14 10.86 PGF IL6 IL10 CXCL8 CXCL10 CSF3
15 10.78 IL6 CXCL8 CRP
16 10.71 IL6 IL10 CXCL8 CXCL10 CSF3

GO Terms for Acute Pyelonephritis

Cellular components related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 PGF NAMPT LCN2 IL6 IL10 ESM1
2 cell GO:0005623 9.7 LCN2 IL6 CXCR2 CXCR1 CXCL10 CALCA
3 extracellular space GO:0005615 9.47 PGF NAMPT LCN2 IL6 IL10 GPT

Biological processes related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 PGF NAMPT IL6 IL10 CXCR2 CXCR1
2 cell-cell signaling GO:0007267 9.88 PGF NAMPT CXCL10 CALCA
3 immune response GO:0006955 9.87 IL6 IL10 CXCR2 CXCR1 CXCL8 CXCL10
4 aging GO:0007568 9.85 NAMPT IL10 CALCA ADM
5 cytokine-mediated signaling pathway GO:0019221 9.85 LCN2 IL6 IL10 CXCL8 CXCL10 CSF3
6 chemotaxis GO:0006935 9.84 CXCR2 CXCR1 CXCL8 CXCL10
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 CXCR2 CXCR1 CALCA ADM
8 female pregnancy GO:0007565 9.81 PGF NAMPT ADM
9 positive regulation of angiogenesis GO:0045766 9.81 PGF CXCR2 CXCL8 ADM
10 cell chemotaxis GO:0060326 9.8 CXCR2 CXCR1 CXCL10
11 calcium-mediated signaling GO:0019722 9.78 CXCR2 CXCR1 CXCL8
12 neutrophil chemotaxis GO:0030593 9.76 CXCR2 CXCR1 CXCL8 CXCL10
13 positive regulation of cell proliferation GO:0008284 9.76 PGF NAMPT IL6 ESM1 CXCR2 CXCL10
14 response to glucocorticoid GO:0051384 9.74 IL6 IL10 ADM
15 cellular response to lipopolysaccharide GO:0071222 9.73 LCN2 IL6 IL10 CXCL8 CXCL10 CSF3
16 chemokine-mediated signaling pathway GO:0070098 9.71 CXCR2 CXCR1 CXCL8 CXCL10
17 leukocyte chemotaxis GO:0030595 9.65 IL10 CXCL8 CXCL10
18 positive regulation of leukocyte chemotaxis GO:0002690 9.63 IL6 CXCR2
19 neutrophil activation GO:0042119 9.62 CXCR2 CXCL8
20 response to molecule of bacterial origin GO:0002237 9.61 IL10 CXCL8
21 branching involved in labyrinthine layer morphogenesis GO:0060670 9.6 IL10 ADM
22 negative regulation of lipid storage GO:0010888 9.59 IL6 CRP
23 neutrophil mediated immunity GO:0002446 9.58 IL6 ACE
24 amylin receptor signaling pathway GO:0097647 9.56 CALCA ADM
25 interleukin-8-mediated signaling pathway GO:0038112 9.49 CXCR2 CXCR1
26 receptor internalization GO:0031623 9.35 CXCR2 CXCR1 CXCL8 CALCA ADM
27 inflammatory response GO:0006954 9.23 IL6 IL10 CXCR2 CXCL8 CXCL10 CRP

Molecular functions related to Acute Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 PGF IL6 IL10 CSF3
2 drug binding GO:0008144 9.58 NAMPT ALB ACE
3 C-X-C chemokine receptor activity GO:0016494 9.37 CXCR2 CXCR1
4 interleukin-8 binding GO:0019959 9.26 CXCR2 CXCR1
5 enterobactin binding GO:1903981 9.16 LCN2 ALB
6 cytokine activity GO:0005125 9.1 NAMPT IL6 IL10 CXCL8 CXCL10 CSF3
7 interleukin-8 receptor activity GO:0004918 8.96 CXCR2 CXCR1

Sources for Acute Pyelonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....